左卡尼汀对维持性血液透析患者微炎症状态及相关炎症因子的影响被引量：29

Effects of Levocarnitine on Microinflammatory State and Correlation Factors in Maintenance Hemodialysis Patients

下载PDF

导出

摘要目的探讨静脉注射左卡尼汀对维持性血液透析(maintenance hemodialysis,MHD)患者微炎症状态及相关炎症因子的影响。方法选择透析中心透析龄>12个月的MHD患者68例,随机分为治疗组35例,对照组33例。两组常规治疗相同,治疗组于每次透析结束后给予静脉注射左卡尼汀1g,治疗3个月,分别检测治疗前及治疗1,3个月末患者的血生化指标、超敏C反应蛋白(hs-CRP)、白细胞介素(IL)-6、IL-8、肿瘤坏死因子α(TNF-α)、脂蛋白(a)[Lp(a)]、透析充分性(Kt/V)。结果治疗组1个月后hs-CRP、IL-6、IL-8、TNF-α、Lp(a)平均值较治疗前下降,治疗组与对照组比较差异有统计学意义(均P<0.05)。3个月后治疗组hs-CRP、IL-6、IL-8、TNF-a、Lp(a)平均值较治疗前明显下降,与对照组比较差异有统计学意义(均P<0.01)。结论左卡尼汀可以降低维持性血液透析患者hs-CRP、IL-6、IL-8、TNF-α、Lp(a)浓度,并改善微炎症状态。 Objective To study the effects of levocarnitine by intravenous injection on microinflammatory state and correlation inflammatory factor in maintenance hemodialysis patients.Methods Sixty-eight maintenance hemodialysis（12 months） patients in our dialysis center were enrolled,and were randomly divided into treatment group and control group.Patients in the treatment group were injected with levocarnitine（1.0 g once） after every dialysis for 3 months,while patients in the control group only accepted routine hemodialysis therapy.Blood biochemical indicators,serum hs-CRP,IL-6,IL-8,TNF-a,Lp（a） and Kt/V value were measured and compared at the experiment onset,1 month and 3 months later.Results The hs-CRP,IL-6,IL-8,TNF-α and Lp（a） level were obviously decreased in the treatment group after 1 month,and there were significantly difference between two groups（P0.05）.All above markers in the treated group were descended further after 3 months,and the difference between two groups was more significant（P0.01）.Conclusion Levocarnitine can reduce serum level of hs-CRP,IL-6,IL-8,TNF-α and Lp（a） and improve the microinflammatory state in maintenance hemodialysis patients.

作者喻业安夏瑗瑜尹青桥李相友

机构地区武汉大学医学院附属同仁医院肾内科

出处《医药导报》 CAS 2011年第1期55-58,共4页 Herald of Medicine

关键词左卡尼汀血液透析微炎症状态 Levocarnitine Maintenance hemodialysis Microinflammatory state

分类号 R977.9 [医药卫生—药品]

引文网络
相关文献

参考文献15

1YEUN J Y ,LEVINE R A ,MANTADILOK N , et al. C - reactive protein predicts all cause and cardiovascular mortality in hemodialysis patients [J].Am J Kidney Dis , 2000,35 ( 3 ) :469-476.
2CALO L A, BERTI P L, PAGNIN E. Antioxidants, earnitine and erythropoietin [ J ]. G Ital Nefrol, 2006,23 ( Suppl34) : 47-50.
3SCHOMIG M, EISENHANDT A, RITZ E. The microinflammatoty state of uremia [ J]. Blood Purif, 2000, 18 (4): 327 -332.
4STENVINKEL P, HEIMBURGER O, PAULTRE F,et al. Strong association between malnutrition, inflammation, and at herosclerosis in chronic renal failure [ J ]. Kidney Int, 1999,55 (5) :1899-1911.
5TSIRPANLIS G, CHATZIPANAGIOTOU S, NICOLAOU C. Microinflammation versus inflammation in chronic renal failure patients [ J]. Kidney Int, 2004, 66 ( 5 ) :2093-2094.
6TSIRPANLIS G, BAGOS P, IOANNOU D,et al. Inflammation and microinflammation in hemodialysis paitients, a longitudinal study [ J ]. Nephrol Dialysis Transplant, 2003, 18(4) :720.
7RIDKER P M, RIFAI N, ROSE L, et al. Comparison of C- reactive protein and low-density lipoprotein cholesterol level in the prediction of first cardiovascular events [ J ]. N Engl J Med,2002,347(20) : 1557-1565.
8BELLINGHIERI G, SANTORO D, CALVANI M, et al, Carnitine and hemodialysis[ J]. Am J Kidney Dis,2003,41 (3 Suppl 1) :116-122.
9GALLE J. Atherosclerosis and arteriolitis: implications for therapy of cardiovascular disease [ J ]. Herz,2004,29 ( 1 ) : 4-11.
10GIOVANNI P, GIUSEPPE G, SIMONA S, et al. Inflammation and carnitinein hemodialysis patients [ J ]. J Ren Nutr,2005,15 ( 11 ) : 8-12.